Active Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) Using Fibroblasts Transfected With DNA From Autologous Tumor (Phase IB Study).

Trial Profile

Active Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) Using Fibroblasts Transfected With DNA From Autologous Tumor (Phase IB Study).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs IC 1001 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Aug 2012 Actual initiation date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 02 Jun 2012 Trial design presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 25 May 2011 Planned End Date changed from 1 Jan 2022 to 1 Jan 2025 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top